Successful Chemotherapy Following Autologous Stem Cell Transplantation in Multiple Myeloma and Multi-organ Dysfunction with Infiltration of Eosinophils: A Case Report by Lee, Ho Sup et al.
Successful Chemotherapy Following Autologous Stem
Cell Transplantation in Multiple Myeloma and Multi-organ
Dysfunction with Infiltration of Eosinophils: A Case Report
Introduction 
Eosinophils are derived from multipotent and lineage-committed
hematopoietic stem cells [1]. The major growth factors for eosinophils
are interleukin (IL)-3, IL-5, and granulocyte monocyte-colony
stimulating factor (GM-CSF). These regulators are produced by
activated T lymphocytes, mast cells, and tissue stroma cells [2,3].
Peripheral blood eosinophilia is defined as an absolute eosinophil
count (AEC)0.510
9/L. The degree of blood eosinophilia is
classified as either mild (AEC, 0.510
9/L to 1.510
9/L), moderate
(AEC, 1.510
9/L to 5.010
9/L) or severe (AEC,ĥ5.010
9/L) [3,4].
In general, eosinophilia is divided into either familial or acquired
types. Acquired eosinophilia is classified as primary or clonal
eosinophilia (based on the presence of histological, cytogenetic or
molecular markers of a myeloid malignancy in the bone marrow),
secondary eosinophilia (a cytokine-driven reactive phenomenon),
and idiopathic eosinophilia (neither secondary nor clonal), which
includes idiopathic hypereosinophilic syndrome (HES) [3,4]. The
causes of secondary eosinophilia are infections (mostly helminthic),
drugs, pulmonary eosinophilia, autoimmune diseases, inflammation,
endocrinopathies, and malignancies [2-4]. Both hematopoietic and
solid neoplasms may be associated with peripheral blood eosinophilia
[3,5]. However, there have been few reports on the association
between multiple myeloma (MM) or plasma cell disorders and
eosinophilia, and the few cases that have been reported have found
outcomes after chemotherapy to be poor [6-8].
We now report a case of a 31-year-old male with MM who had
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Eosinophils are derived from hematopoietic stem cells. Peripheral blood eosinophilia is defined
as an absolute eosinophil count of 0.510
9/L. Eosinophilia is classified into primary or
clonal eosinophilia, secondary eosinophilia, and idiopathic categories including idiopathic
hypereosinophilic syndrome. Both hematopoietic and solid neoplasms may be associated
with peripheral blood eosinophilia, but multiple myeloma is rarely associated with eosinophilia.
We now report the case of a 31-year-old man with multiple myeloma associated with marked
eosinophilia who developed multiple organ dysfunction with infiltration of eosinophils. He
recovered after treatment with chemotherapy followed by autologous stem cell transplantation. 
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pISSN 1598-2998 eISSN 2005-9256marked absolute peripheral blood and bone marrow eosinophilia,
leading to multiple organ dysfunction with eosinophil infiltration.
After chemotherapy followed by autologous stem cell trans-
plantation (ASCT), the patient achieved complete remission (CR).
Case Report
A 31-year-old man was hospitalized for fever, fatigue, and
abdominal discomfort. He reported no recent travel history, there
Cancer Res Treat. 2011;43(3):199-203
200 CANCER  RESEARCH AND  TREATMENT
C B A
D E F
Fig. 2. (A) A right pleural effusion was noted, with focal consolidation or subsegmental atelectasis of the right middle lobe. (B, C)
Hepatosplenomegaly of both hepatic lobes was present without a definite focal lesion. The perihepatic space contained fluid. The lymph nodes
were enlarged in the peripancreatic, mesenteric and aortocaval areas. (D) Minimal pericardial effusion, septal hypertrophy and mild global
hypokinesia of the left ventricle were noted on echocardiography. (E) There was a relaxation abnormality in the mitral valve inflow pattern. (F)
Diffuse-fashioned erythema of the mucosa was noted in the antrum of the stomach.
A B
Fig. 1. (A) A bone marrow biopsy showed hypercellular marrow (ĥ90%) with numerous eosinophils and plasma cells (H&E staining,1,000).
(B) Bone marrow aspiration revealed hypercellular marrow with many eosinophils and plasma cells (Wright staining,1,000).was no history of urticarial or other allergic symptoms, and he had
no history of alcoholism. Vital signs at the time of admission were
as follows: temperature, 38.3; pulse, 92 beats per minute; blood
pressure, 125/75 mm Hg; and respiratory rate, 18 breaths per minute.
The initial physical examination revealed hepatosplenomegaly, a
distended abdomen with ascites and significant pitting edema in
both lower limbs. An initial complete blood count (CBC) found a
hemoglobin (Hb) level of 8.3 g/dL, a white blood cell count (WBC)
Ho Sup Lee, et al_MM with HES 
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Fig. 4. Flow cytometric detection of plasma cells. Identification of plasma cells in pleural and peritoneal fluids of the patient using the plasma cell
markers CD38 and CD138. These cells are high-intensity CD38-positive and CD138-positive. (A) Plasma cell markers were positive (CD138,
60.12%; CD38, 96.2%) in the peritoneal fluid. (B) Plasma cell markers were positive (CD138, 96.18%; CD38, 99.8%) in the pleural fluid.
A
C D
B
Fig. 3. (A) The liver parenchyme showed infiltrations of numerous eosinophils and plasma cells on the hemorrhage focus (H&E staining,200).
(B) The liver parenchyme and portal areas showed infiltration of eosinophils and plasma cells on the hemorrhage foci (H&E staining,400). (C,
D) Plasma cells and eosinophils were observed in the pleural fluid and the ascitic fluid (D) (H&E staining, C,1,000; D,1,000). of 12,300/Ǻ L and a platelet count of 77,000/Ǻ L. A differential WBC
showed 36% neutrophils (4,430/Ǻ L), 28% lymphocytes (3,440/Ǻ L),
and 35% eosinophils (4,310/Ǻ L), but did not include circulating
myeloid precursors or other left-shifted neutrophils. The patient had
also suffered from eosinophilia eight months previous (Hb, 13.4 g/dL;
WBC, 8,590/Ǻ L [eosinophils, 2,233/Ǻ L]; platelet count, 203,000/Ǻ L).
Other laboratory findings were as follows: lactate dehydrogenase,
496 IU/L; protein, 12.7 g/dL; albumin, 2.2 g/dL; IgE,ĥ3,000 IU/mL;
IgG,ĥ5,000 mg/dL; IgA, 152.7 mg/dL; IgM, 162.8 mg/dL; Bence-
Jones protein (+); ǰ 2-microglobulin, 4.70 mg/L; serum vitamin B12
level, 1,428 pg/mL; folic acid level, 2.91 ng/mL; serum free kappa
light chain, 566.0 mg/mL; serum free lambda light chain, 765.0
mg/mL; anti-nuclear antibody (-); anti-double strand DNA antibody
(-); anti-mitochondrial antibody (-); hepatitis B virus surface antigen
(-); and anti-hepatitis C virus antibody (-) (serum tryptase was un-
available for testing). Bone marrow aspiration and biopsy showed
hypercellular marrow with high levels of eosinophilic (19.1%) and
plasma (22.9%) cells with no increases in other matured myeloid
precursors (Fig. 1)A chromosomal study was normal (46, XY), and
fluorescence in situ hybridization (FISH) analyses for platelet-
derived growth factor receptor (PDGFR) and BCR/ABL were
negative. Our diagnostic evaluation of the eosinophilia included a
stool specimen negative for parasitic infection and a negative multiple
antigen simultaneous test (MAST). A computed tomography (CT)
scan of the chest showed effusion of the right pleura (Fig. 2A).
Abdominal CT revealed hepatosplenomegaly of both hepatic lobes
without a definite focal lesion, fluid in the perihepatic space and
lymph node enlargement in the peripancreatic, mesenteric, and
aortocaval areas (Fig. 2B and C). An echocardiogram showed
minimal pericardial effusion, septal hypertrophy and mild global
hypokinesia of the left ventricle (Fig. 2D and E). Endoscopy found
diffuse-fashioned erythema of the stomach mucosa in the antrum
(Fig. 2E). We could not perform a biopsy of the heart or stomach
because the patient was prone to complications from invasive
procedures (e.g., excessive bleeding and pleural effusion). A liver
biopsy showed parenchymal infiltration of numerous eosinophils
and plasma cells on the hemorrhage focus (Fig. 3A and B). Plasma
cell markers were positive in the peritoneal (CD138, 60.12%;
CD38, 96.2%) and pleural (CD138, 96.18%; CD38, 99.8%) fluids
(Fig. 4). The cytology results of the ascites and pleural fluids showed
plasma cells and eosinophils (Fig. 3C and D). Based on these
results, eosinophilia involving the bone marrow, liver, and lungs
was confirmed, and eosinophilia involving the peritoneal cavity,
heart, and stomach were considered possibilities. Moreover, the
patient’s albumin/globulin ratio was reversed. A monoclonal peak
was observed in the gammaglobulin fraction from serum protein
electrophoresis (Fig. 5A), and immunofixation electrophoresis
revealed IgG, kappa and lambda paraproteins (Fig. 5B). Therefore, the
patient was diagnosed with MM with biclonal gammopathy. Three
weeks after starting dexamethasone, the patient was treated with a
bortezomib (Velcade
⃕, Ben Venue Laboratories, Inc., Bedford, OH)
plus dexamethasone (VD) regimen every three weeks. Four months
following the start of the VD regimen, the patient’s laboratory
findings improved. The patient then underwent ASCT. His
treatment was maintained (with thalidomide plus dexamethasone)
for six months after ASCT. Currently, he has finished treatment and
has been followed-up with laboratory tests for nine months. A recent
CBC revealed an Hb level of 14.1 g/dL, a WBC of 4,100/Ǻ L with a
differential cell count of 10% eosinophils (410/Ǻ L) and a platelet
count of 127,000/Ǻ L. The eosinophil count of the patient did not
exceed 1.510
9/L on consecutive readings after initiation of ASCT.
Other laboratory findings included an IgG concentration of 1,085
mg/dL, serum free kappa/lambda light chain of 16.60/17.60 mg/mL,
a kappa/lambda ratio of 0.94, and negative immunofixation and ǰ 2-
microglobulin of 1.70 mg/L. The laboratory findings were all in
normal ranges. He is now in a status of CR for MM. His liver and
spleen have decreased in size, and they and other organs have
recovered their functionalities. 
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Fig. 5. (A) A monoclonal peak is observed in the gammaglobulin fraction (7.73 g/dL) in serum protein electrophoresis. (B) IgG (G), kappa (Ǹ ),
and lambda (ǹ ) lanes were identified in serum immunofixation electrophoresis. SP, standard protein; A, IgA; M, IgM.Ho Sup Lee, et al_MM with HES 
Discussion 
A wide variety of solid tumors (predominantly carcinomas of the
lung, head and neck, uterus, breast, pancreas, colon and rectum,
thyroid gland, adrenal glands, and the biliary tract) may be associated
with eosinophilia [5,9]. A number of lymphoid neoplasms may be
accompanied by eosinophilia, including Hodgkin’s disease and T-
cell lymphomas and, less frequently, B-cell non-Hodgkin’s lym-
phomas, natural killer cell neoplasms, and other B cell malignancies
[2,3,5]. There have been some case reports of eosinophilia associated
with lymphoid malignancies [10,11]. However, there have been few
reports on eosinophilia with MM or plasma cell disorders [6,7]. In
Korea, only one case has been diagnosed as chronic eosinophilic
leukemia with MM [8]. In our case, primary and clonal eosinophilia
were excluded based on the results of FISH and chromosomal
studies, and myeloproliferative disease was ruled out based on the
absence of circulating myeloid precursors and normal chromosomal
and bone marrow findings, without a left shift in maturation except
for eosinophils and plasma cells. In Japan, a case of MM and chronic
hepatitis C has been reported [12]. According to the laboratory
findings of our case, the patient did not have a chronic liver disease.
We diagnosed secondary eosinophilia associated with MM because
the patient had an eosinophilia-concomitant hematologic malignancy.
There is no acceptable mechanism to explain the occurrence of
peripheral blood eosinophilia in patients with plasma cell disorders.
Stefanini et al. [13] suggest four hypotheses. First, the release of a
protein from necrotic tumor cells may result in eosinophilia. Second,
the presence of a metastatic tumor in the bone marrow may stimulate
eosinophilopoiesis. Third, eosinophilia may represent a genetic or
familial response to malignant tumors. Finally, neoplastic cells may
actively secrete substances that either directly or indirectly (via
secretion by other cells) result in eosinophilia [13]. According to
Stefanini et al. [13], IL-3, IL-5 and GM-CSF promote eosinophi-
lopoiesis in patients with hematologic malignancies. However, we
could not study these relationships in our case, because IL-3, IL-5,
and GM-CSF levels were not measured in our patient.  
In our case, biclonal gammopathy was noted (Fig. 5B). There
have been few reports on MM with biclonal gammopathy, and its
incidence is about 1% of all monoclonal gammopathies. MM with
biclonal gammopathy is associated with malignant lymphoma [14].
Imatinib is the standard treatment in patients with clonal eosino-
philia including PDGFR mutations, and cytoreductive therapy or
steroids are the treatments of choice with HES. Secondary eosinophilia
can be addressed by treating the underlying disease. Drug-refractory
eosinophilia is usually treated with chemotherapy and allogenic stem
cell transplantation [2,4,9,15]. The main therapy for plasma cell
disorders with eosinophilia has been melphalan, vincristine,
adriamycin and dexamethasone (VAD) or cyclophosphamide [6,7].
The majority of these published cases did not achieve sustained
responses, and plasma cells or eosinophils increased in the bone
marrow or the peripheral blood of these patients shortly after termi-
nation of the treatment. Life expectancies in these cases were short.  
At present, there is no standard treatment for patients with MM and
eosinophilia despite the poor response and prognosis. Even though
there are no reports that suggest treatment via hematopoietic stem cell
transplantation in cases similar to ours, we performed ASCT after
induction chemotherapy with a VD regimen. Through this treatment,
our patient achieved CR of at least six months without other therapies.
Long term follow-up is required to confirm the sustained response. 
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